Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries - Sung, H.; Ferlay, J.; Siegel, R. L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. (CA Cancer J Clin, 2021)

Five-year outcomes from the randomized, phase iii trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer - Borghaei, H.; Gettinger, S.; Vokes, E. E.; Chow, L. Q. M.; Burgio, M. A.; Castro, C. J. (J Clin Oncol, 2021)

The effect of advances in lung-cancer treatment on population mortality - Howlader, N.; Forjaz, G.; Mooradian, M. J.; Meza, R.; Kong, C. Y.; Cronin, K. A. (N Engl J Med, 2020)

Atezolizumab versus docetaxel in pretreated patients with nsclc: final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials - Mazieres, J.; Rittmeyer, A.; Gadgeel, S.; Hida, T.; Gandara, D. R.; Cortinovis, D. L. (J Thorac Oncol Off Publ Int Assoc Study Lung Cancer, 2021)

How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer - Peters, S.; Reck, M.; Smit, E. F.; Mok, T.; Hellmann, M. D. (Annal Oncol Off J Eur Soc Med Oncol, 2019)

Potential biomarkers for immunotherapy in non-small-cell lung cancer - Wang, X.; Qiao, Z.; Aramini, B.; Lin, D.; Li, X.; Fan, J. (Cancer Metastasis Rev, 2023)

The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC - Jin, Y.; Dong, H.; Xia, L.; Yang, Y.; Zhu, Y.; Shen, Y. (J Thorac Oncol Off Publ Int Assoc Study Lung Cancer, 2019)

The role of gut microbiota in cancer treatment: friend or foe? - Cheng, W. Y.; Wu, C. Y.; Yu, J. (Gut, 2020)

The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non-small cell lung cancer - Hakozaki, T.; Richard, C.; Elkrief, A.; Hosomi, Y.; Benlaïfaoui, M.; Mimpen, I. (Cancer Immunol Res, 2020)

Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab - Martini, G.; Ciardiello, D.; Dallio, M.; Famiglietti, V.; Esposito, L.; Corte, C. M. D. (Int J Cancer, 2022)

Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment - Botticelli, A.; Vernocchi, P.; Marini, F.; Quagliariello, A.; Cerbelli, B.; Reddel, S. (J Transl Med, 2020)

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients - Gopalakrishnan, V.; Spencer, C. N.; Nezi, L.; Reuben, A.; Andrews, M. C.; Karpinets, T. V. (Science, 2018)

The airway microbiome and childhood asthma - what is the link? - Dick, S.; Turner, S. (Acta Medica Academica, 2020)

Effects of lumacaftor-ivacaftor on airway microbiota-mycobiota and inflammation in patients with cystic fibrosis appear to be linked to pseudomonas aeruginosa chronic colonization - Enaud, R.; Lussac-Sorton, F.; Charpentier, E.; Velo-Suárez, L.; Guiraud, J.; Bui, S. (Microbiol Spectr, 2023)

Bacterial species and inflammatory cell variability in respiratory tracts of patients with chronic obstructive pulmonary disease exacerbation: a multicentric study - Salama, K. S. M.; Moazen, E. M.; Elsawy, S. B.; Kotb, S. F.; Mohammed, E. M.; Tahoun, S. A. (Infect Drug Resist, 2023)

The microbiota of the respiratory tract: gatekeeper to respiratory health - Man, W. H.; Steenhuijsen Piters, W. A.; Bogaert, D. (Nat Rev Microbiol, 2017)

The lung microbiota of healthy mice are highly variable, cluster by environment, and reflect variation in baseline lung innate immunity - Dickson, R. P.; Erb-Downward, J. R.; Falkowski, N. R.; Hunter, E. M.; Ashley, S. L.; Huffnagle, G. B. (Am J Respir Crit Care Med, 2018)

Lung microbiome: new insights into the pathogenesis of respiratory diseases - Li, R.; Li, J.; Zhou, X. (Signal Transduct Target Ther, 2024)

Relationship of the lung microbiome with PD-L1 expression and immunotherapy response in lung cancer - Jang, H. J.; Choi, J. Y.; Kim, K.; Yong, S. H.; Kim, Y. W.; Kim, S. Y. (Respir Res, 2021)

The microbiome, cancer, and cancer therapy - Helmink, B. A.; Khan, M. A. W.; Hermann, A.; Gopalakrishnan, V.; Wargo, J. A. (Nat Med, 2019)

Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine - Campesato, L. F.; Budhu, S.; Tchaicha, J.; Weng, C. H.; Gigoux, M.; Cohen, I. J. (Nat Commun, 2020)

Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis - Labadie, B. W.; Bao, R.; Luke, J. J. (Clin Cancer Res Off J Am Assoc Cancer Res, 2019)

Dietary tryptophan metabolite released by intratumoral lactobacillus reuteri facilitates immune checkpoint inhibitor treatment - Bender, M. J.; McPherson, A. C.; Phelps, C. M.; Pandey, S. P.; Laughlin, C. R.; Shapira, J. H. (Cell, 2023)

Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer - Tintelnot, J.; Xu, Y.; Lesker, T. R.; Schönlein, M.; Konczalla, L.; Giannou, A. D. (Nature, 2023)

PD-1 inhibitors raise survival in NSCLC. Cancer Discov 2014;4(1):6 https://doi.org/10.1158/2159-8290.Cd-nb2013-164

Microbiota and lung cancer - Goto, T. (Semin Cancer Biol, 2022)

Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions - Lee, S. H.; Sung, J. Y.; Yong, D.; Chun, J.; Kim, S. Y.; Song, J. H. (Lung Cancer, 2016)

Lower airway dysbiosis affects lung cancer progression - Tsay, J. J.; Wu, B. G.; Sulaiman, I.; Gershner, K.; Schluger, R.; Li, Y. (Cancer Discov, 2021)

Intratumoral presence of the genotoxic gut bacteria pks(+) E. coli, enterotoxigenic bacteroides fragilis, and fusobacterium nucleatum and their association with clinicopathological and molecular features of colorectal cancer - Joo, J. E.; Chu, Y. L.; Georgeson, P.; Walker, R.; Mahmood, K.; Clendenning, M. (British J Cancer, 2024)

Association of probiotic clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer - Tomita, Y.; Ikeda, T.; Sakata, S.; Saruwatari, K.; Sato, R.; Iyama, S. (Cancer Immunol Res, 2020)

Evaluating the role of probiotics in the prevention and management of age-related diseases - Kiousi, D. E.; Kouroutzidou, A. Z.; Neanidis, K.; Matthaios, D.; Pappa, A.; Galanis, A. (Int J Mol Sci, 2022)

How the ageing microenvironment influences tumour progression - Fane, M.; Weeraratna, A. T. (Nat Rev Cancer, 2020)

The gut microbial diversity of colon cancer patients and the clinical significance - He, T.; Cheng, X.; Xing, C. (Bioengineered, 2021)

Chlamydia pneumoniae infections and development of lung cancer: systematic review - Premachandra, N. M.; Jayaweera, J. (Infect Agents Cancer, 2022)

The microbiota of breast tissue and its association with breast cancer - Urbaniak, C.; Gloor, G. B.; Brackstone, M.; Scott, L.; Tangney, M.; Reid, G. (Appl Environ Microbiol, 2016)

The potential role of lung microbiota in lung cancer attributed to household coal burning exposures - Hosgood, H. D.; Sapkota, A. R.; Rothman, N.; Rohan, T.; Hu, W.; Xu, J. (Environ Mol Mutagen, 2014)

Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects - Liu, H. X.; Tao, L. L.; Zhang, J.; Zhu, Y. G.; Zheng, Y.; Liu, D. (Int J Cancer, 2018)

The gut microbiome is associated with clinical response to anti-pd-1/pd-l1 immunotherapy in gastrointestinal cancer - Peng, Z.; Cheng, S.; Kou, Y.; Wang, Z.; Jin, R.; Hu, H. (Cancer Immunol Res, 2020)

Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients - Zhang, C.; Wang, J.; Sun, Z.; Cao, Y.; Mu, Z.; Ji, X. (Cancer Sci, 2021)

Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status - Dora, D.; Ligeti, B.; Kovacs, T.; Revisnyei, P.; Galffy, G.; Dulka, E. (Oncoimmunology, 2023)

Cold tumors: a therapeutic challenge for immunotherapy - Bonaventura, P.; Shekarian, T.; Alcazer, V.; Valladeau-Guilemond, J.; Valsesia-Wittmann, S.; Amigorena, S. (Front Immunol, 2019)

Mechanisms of probiotic bacillus against enteric bacterial infections - Zhu, J.; Chen, Y.; Imre, K.; Arslan-Acaroz, D.; Istanbullugil, F. R.; Fang, Y. (One Health Adv, 2023)

GPR31-dependent dendrite protrusion of intestinal CX3CR1(+) cells by bacterial metabolites - Morita, N.; Umemoto, E.; Fujita, S.; Hayashi, A.; Kikuta, J.; Kimura, I. (Nature, 2019)

The gut microbiome and efficacy of cancer immunotherapy - Roviello, G.; Iannone, L. F.; Bersanelli, M.; Mini, E.; Catalano, M. (Pharmacol Ther, 2022)

Lung inflammation and disease: a perspective on microbial homeostasis and metabolism - Mendez, R.; Banerjee, S.; Bhattacharya, S. K.; Banerjee, S. (IUBMB Life, 2019)

A pan-cancer analysis of the microbiome in metastatic cancer - Battaglia, T. W.; Mimpen, I. L.; Traets, J. J. H.; Hoeck, A.; Zeverijn, L. J.; Geurts, B. S. (Cell, 2024)

Characterizing human lung tissue microbiota and its relationship to epidemiological and clinical features - Yu, G.; Gail, M. H.; Consonni, D.; Carugno, M.; Humphrys, M.; Pesatori, A. C. (Genome Biol, 2016)

Commensal microbiota promote lung cancer development via γδ t cells - Jin, C.; Lagoudas, G. K.; Zhao, C.; Bullman, S.; Bhutkar, A.; Hu, B. (Cell, 2019)

Gut microbiome affects the response to immunotherapy in non-small cell lung cancer - Ren, S.; Feng, L.; Liu, H.; Mao, Y.; Yu, Z. (Thorac cancer, 2024)

Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond - Muller, A. J.; Manfredi, M. G.; Zakharia, Y.; Prendergast, G. C. (Seminar Immunopathol, 2019)

Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues - Théate, I.; Baren, N.; Pilotte, L.; Moulin, P.; Larrieu, P.; Renauld, J. C. (Cancer Immunol Res, 2015)

Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer - Jia, D.; Wang, Q.; Qi, Y.; Jiang, Y.; He, J.; Lin, Y. (Cell, 2024)

Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1/Kyn/AHR axis - Fong, W.; Li, Q.; Ji, F.; Liang, W.; Lau, H. C. H.; Kang, X. (Gut, 2023)

Badawy AA (2022) Tryptophan metabolism and disposition in cancer biology and immunotherapy. Biosci Rep. https://doi.org/10.1042/bsr20221682

Bridging of host-microbiota tryptophan partitioning by the serotonin pathway in fungal pneumonia - Renga, G.; D'Onofrio, F.; Pariano, M.; Galarini, R.; Barola, C.; Stincardini, C. (Nat Commun, 2023)

AHR in the intestinal microenvironment: safeguarding barrier function - Stockinger, B.; Shah, K.; Wincent, E. (Nat Rev Gastroenterol Hepatol, 2021)